GLAXOSMITHKLINE has announced that its Fluarix Tetra seasonal influenza immunisation is no longer available in the private market, with all stocks diverted to supply government programs.
"GSK has received urgent requests from governments for additional doses, particularly for the vaccination of children under five years of age," the company said.
"Consequently GSK has taken the decision to divert all of its remaining Fluarix Tetra vaccine doses to these important programs," it added.
GSK also advised of a shortage of its measles, mumps, rubella and varicella combination vaccine Priorix Tetra through until Nov 2019, impacting its ability to supply the product to the National Immunisation Program.
The company's Priorix MMR vaccine is also in short supply for non-government customers due to demand from measles outbreak control programs in several states and territories.
Stocks are also low for rabies vaccine Rabipur along with hepatitis-containing vaccines Havrix and Twinrix, while GSK is also experiencing a "supply constraint" of its Ventolin 5mg nebules due to high global demand.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 May 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 May 19
